CD8A and neoplasm: However, in the clinic, FOLFIRINOX delivery is associated with increased tumor-infiltrating CD8+ T lymphocytes (TILs), decreased circulating regulatory T cells (Tregs), and can increase tumoral PD-L1 expression (41–43).